Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04525534 · ClinicalTrials.gov registry record
Plasma Concentration of Biological Markers in Placenta Accreta Spectrum
A clinical trial, sponsored by University of Arkansas.
- Terminated
- Registry status
- 19
- Enrollment target
NCT04525534: Clinical Trial study, sponsored by University of Arkansas.
NCT04525534 is a clinical trial that was terminated before completion, run by University of Arkansas. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04525534 was terminated before completion, sponsored by University of Arkansas.
- TERMINATED
- Registry status
- 19 participants
- Enrollment target
Study Summary
The purpose of this exploratory study is to determine how well maternal serum biomarkers and placental micro-particles (MP) correlate with placenta accreta spectrum (PAS) at the time of cesarean delivery in women with suspected PAS compared to women without PAS. Our aim is to determine if women with PAS have a unique MP and protein signature at the time of delivery compared with women without PAS.
Primary Outcome
Determine quantitatively the level of placental-derived MPs which may be altered in 10 subjects with PAS and 10 phenotypically-matched controls.
Interventions
- OTHER There is no other intervention, only clinical treatment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2020-08-30 |
| Est. Completion | 2023-07-10 |
Why NCT04525534 stopped before completion
NCT04525534 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which There is no other intervention, only clinical treatment. is the first listed.
NCT04525534 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04525534 about?
NCT04525534 is a clinical study titled "Plasma Concentration of Biological Markers in Placenta Accreta Spectrum". The purpose of this exploratory study is to determine how well maternal serum biomarkers and placental micro-particles (MP) correlate with placenta accreta spectrum (PAS) at the time of cesarean delivery in women with suspected PAS compared to women without PAS. Our aim is to determine if women with...
What is the current status of trial NCT04525534?
This trial is currently terminated. The enrollment target is 19 participants. The study started on 2020-08-30. Estimated completion is 2023-07-10.
What interventions are being tested in trial NCT04525534?
The interventions under investigation include: There is no other intervention, only clinical treatment. (OTHER).
Who is sponsoring clinical trial NCT04525534?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI